Pharmaceuticals and Medical Devices Agency (PMDA)

Iterating on FDA, EMA expedited approvals with stricter requirements for postmarket data submissions

Former BARDA Director Bright leaving NIH Rick Bright, the former director of the Biomedical Advanced Research and Development Authority and HHS deputy assistant secretary for preparedness and

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

Belgian regenerative medicine biotech Promethera makes the case for expanding in Asia

Why industry is balking at Japan’s new pricing reforms

How FDA’s regenerative medicine framework puts the U.S., Japan and Europe on the same page

How Japan’s MHLW is grappling with drug pricing, access and innovation

Why companies want flexibility in guidance on PK modeling tools